HC Wainwright Reiterates “Buy” Rating for Emergent BioSolutions (NYSE:EBS)

Emergent BioSolutions (NYSE:EBS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 158.84% from the company’s current price.

A number of other analysts also recently issued reports on the company. Benchmark raised their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Monday, February 17th.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $5.80 on Tuesday. The company has a market capitalization of $314.00 million, a P/E ratio of -1.41 and a beta of 1.62. The company’s 50-day moving average is $9.43 and its 200 day moving average is $9.02. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a fifty-two week low of $1.82 and a fifty-two week high of $15.10.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The firm had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. During the same period in the previous year, the company earned ($0.77) earnings per share. On average, equities research analysts forecast that Emergent BioSolutions will post -0.63 earnings per share for the current year.

Hedge Funds Weigh In On Emergent BioSolutions

A number of large investors have recently made changes to their positions in EBS. State Street Corp increased its holdings in Emergent BioSolutions by 864.7% during the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 1,713,200 shares during the period. Oak Hill Advisors LP purchased a new position in shares of Emergent BioSolutions during the 3rd quarter valued at $9,296,000. Millennium Management LLC increased its holdings in shares of Emergent BioSolutions by 83.0% in the fourth quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock worth $14,167,000 after purchasing an additional 671,947 shares during the period. Invesco Ltd. raised its position in shares of Emergent BioSolutions by 70.9% in the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after buying an additional 638,995 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Emergent BioSolutions by 67.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after buying an additional 444,790 shares in the last quarter. 78.40% of the stock is owned by institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.